JLS Fund
VC Fund
New York, United States
JLS Fund is a venture capital firm that invests in the psychedelics and technology intersection.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 11%
- Fund size:
- $5.3M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries JLS Fund invests in
Stages JLS Fund invests in
Countries JLS Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 3 (33%)
- Biotechnology 3 (33%)
- Medical 2 (22%)
- Mental Health 2 (22%)
- Pharmaceutical 2 (22%)
Stage
- Seed 3 (33%)
- Series A 3 (33%)
- Series B 1 (11%)
- Post-IPO Equity 1 (11%)
Country
- United States 6 (67%)
- Canada 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Simeon Schnapper
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 1 | Find email | |
Brendan Hussey
Vice President
|
Vice President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline. | $25M / Series A / Jul 01, 2024 | ||
| Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression. | $39M / Series B / Dec 15, 2022 | ||
| Homecoming is a provider of patient engagement tools for psychedelic therapy. | $4M / Seed / Apr 07, 2022 | ||
| Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge ofthe mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend. | $1.4M / Seed / Feb 15, 2022 | ||
| Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge ofthe mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend. | $1.6M / Seed / Nov 04, 2021 | ||
| Psilera develops therapies aimed at neurological and psychiatric disorders by leveraging neuroplastogens, compounds that promote brain plasticity without hallucinogenic effects. The company builds a proprietary library of serotonergic compounds and applies computational tools to design molecules for conditions such as alcohol use disorder andfrontotemporal dementia. Its research pipeline emphasizes non-hallucinogenic derivatives of psychedelic compounds to provide safe and scalable treatment options. Psilera integrates medicinal chemistry, neuroscience, and pharmacology to create small-molecule drugs that address unmet medical needs. Through this approach, the company seeks to expand treatment possibilities for patients facing hard-to-treat neurological conditions. | $2.5M / Seed / Jul 01, 2021 | ||
| TRIPP: Empowering You To Change The Way You FeelNamed the Best VR Meditation App of 2020 by Men’s Health and VR Fitness Insider, The Washington Post calls TRIPP “Meditation-meets-a-video-game-meets-a-Happy-Pill!”TRIPP is the award-winning XR platform designed to address mental and emotional well-being. Proven to drive deep engagement, TRIPPcreates advanced digital products that are based on scientific research and delivered through virtual reality, augmented reality, and mobile devices. TRIPP's platform is currently delivering wellness solutions into consumer households, Fortune 1000 companies and hospitals/clinics worldwide. | $11M / Series A / Jun 25, 2021 | ||
| Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression. | $27M / Series A / May 06, 2021 | ||
| WeSana Health is a life sciences company that provides advancement of psilocybin-based medicine. The company was founded in 2020 by Daniel Carcillo and is headquartered in Homer Glen, Illinois, United States. | $12.8M / Post-IPO Equity / Mar 31, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does JLS Fund invest in?
JLS Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact JLS Fund?
Public channels for JLS Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at JLS Fund?
The team at JLS Fund includes Simeon Schnapper (Founder & Managing Partner) and Brendan Hussey (Vice President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
